LIWANLI Innovation Co., Ltd. (TPE:3054)
Taiwan
· Delayed Price · Currency is TWD 67.30
-3.00 (-4.27%)
Apr 29, 2026, 1:30 PM CST
LIWANLI Innovation Revenue
LIWANLI Innovation had revenue of 135.88M TWD in the quarter ending March 31, 2026, with 643.66% growth. This brings the company's revenue in the last twelve months to 243.15M, up 195.16% year-over-year. In the year 2025, LIWANLI Innovation had annual revenue of 125.54M with 26.61% growth.
Revenue (ttm)
243.15M
Revenue Growth
+195.16%
P/S Ratio
22.32
Revenue / Employee
n/a
Employees
n/a
Market Cap
5.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 125.54M | 26.38M | 26.61% |
| Dec 31, 2024 | 99.16M | 60.27M | 154.98% |
| Dec 31, 2023 | 38.89M | 4.90M | 14.41% |
| Dec 31, 2022 | 33.99M | -13.83M | -28.91% |
| Dec 31, 2021 | 47.81M | -229.07M | -82.73% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SCI Pharmtech | 1.34B |
| Orient Pharma | 1.40B |
| Easywell Biomedicals | 597.41M |
| Formosa Laboratories | 4.85B |
| Orient EuroPharma | 4.60B |
| Merdury Biopharmaceutical | 246.00K |
| Allied Biotech | 849.51M |
| Alar Pharmaceuticals | 2.75M |